manent filter for VTE patients with not only a proximal, free-floating thrombus but also contraindications to anticoagulation therapy or poor life expectancy with malignant disease or age over 80 years. For the other patients, we initially planned to retrieve the filter.
In deploying the GTF we followed the Japanese guideline 16 for use of IVC filters, in which there are no contraindications to the temporary use, but some contraindications to permanent use: (a) occluded IVC; (b) no access to IVC; and (c) pregnancy.
All patients gave written informed consent prior to the implantation.
Implantation
To implant the filter, its sheath was inserted into the right internal jugular or right femoral vein. Inferior vena cavography was performed using the Berman angio-balloon catheter (ARROW, Reading, PA, USA) to identify the section where the renal vein and vena cava merge. A guidewire was used to advance the catheter plus filter (outside diameter 10F) slightly beyond the final position, then the sheath was slowly removed and the filter legs extended. When the filter was appropriately positioned, the end-hook was released to complete the implantation. If there was a problem with the location, the filter was retracted into the sheath before releasing the hook, and the placement process was repeated.
Treatments During Implantation
Intensive anticoagulation with an intravenous bolus of unfractionated heparin, followed by continuous infusion, was performed with no interruption during the implantation process in all the patients without contraindications. The dose of unfractionated heparin was adjusted to maintain the activated partial thromboplastin time at 2-2.5-fold the control value.
Warfarin was administered after thrombolysis. For patients not treated with thrombolysis, warfarin was administered within a few days of beginning anticoagulation with unfractionated heparin. The dose of warfarin was adjusted to maintain the international normalized ratio (INR) of prothrombin time at approximately 2.0. Heparin infusion was discontinued after a therapeutic range of INR (1.5-2.5) was obtained for at least 2 consecutive days. The duration of anticoagulation was basically defined according to the Japanese guideline. 16 Unless there were contraindications to anticoagulation therapy, the patients with the GTF as a permanent filter received warfarin indefinitely, according to expert opinion. 17, 18 Pharmacological and/or pharmacomechanical thrombolysis was used in (a) patients without contraindications of the treatment; (b) patients with pulmonary thromboembolism accompanied by shock or persistent hypotension; (c) patients with right ventricular dysfunction detected on echocardiography, despite stable hemodynamics; and (d) patients with DVT in the iliofemoral vein or IVC. Written consent was given by the patients before treatment. In principle, 240,000 units of urokinase, the only thrombolytic able to be used for the treatment of VTE in Japan at the time this study started, were administered systemically or catheterdirectly, 3 times per day. 19 Ascending venography, venous ultrasonography, or enhanced CT was used every 1-3 days for observation, which enabled the treatment to be suspended until reduction or elimination of the DVT occurred.
Filter Retrieval
The filter was retrieved when the venous thrombus was eliminated after treatment, or when only residual mural thrombus was detected after 1 week or more of treatment with pharmacological and/or pharmacomechanical thrombolysis. Before attempting to retrieve the filter, cavography or enhanced CT was performed to detect thrombus trapped within the filter. The filter was retrieved when the thrombus measured 1×2 cm or smaller, or was not detected at all. If that size thrombus or larger was trapped, further treatment with systemic pharmacological thrombolysis was performed before attempting filter retrieval. 20 For retrieval, a guidewire was advanced to beneath the filter. The puncture site was extended using the dilator, and then the sheath system (introducer, retrieval catheter, sheath, maximum outer diameter 13F) was advanced close to the filter. The introducer was extracted and the loop-wire catheter inserted. The loop-wire was fully extended and the hook snared at the filter tip. The sheath was advanced without pushing the filter out of position and the loop-wire pulled lightly to fix the hook. Care was taken to avoid damaging the IVC wall with the filter anchor. The sheath was then advanced without moving the filter itself, the filter reloaded in the retrieval catheter, and the catheter removed. Just after retrieval, the IVC wall was checked by cavography for any damage or perforation.
Points for Evaluation
The entire implantation and retrieval process was evaluated for the following: indications; implantation approach site; location and period of implantation; technical feasibility of filter placement and retrieval; retrieval time and success rate; reasons for deciding against retrieval; occurrence of symptomatic pulmonary thromboembolism after im- plantation and during/after retrieval of the filter; and rate of complications such as hemorrhage, infection, vascular damage, air embolus, tilting, asymmetrical dilation, displacement, misinsertion, and filter fracture. All patients from whom the GTF was not retrieved because of a huge residual thrombus in the IVC (below the filter), pelvic region, and/or proximal lower extremity received anticoagulant therapy without contraindications. In the chronic phase, we used enhanced CT to evaluate whether or not the filters left permanently were occluded with thrombus. Furthermore, we evaluated whether the struts of the filters penetrates the IVC wall by more than 1 mm.
Results
Patient characteristics are shown in Table 1 . The total dose of urokinase used for the treatment of DVT was 3,100,000±1,900,000 units in 6.1±3.4 days.
As for the method of implantation, 116 filters were implanted using the right internal jugular vein approach and only 2 were implanted using the right femoral vein approach. There were no complications with the implantations. The filters were implanted in the IVC below the renal vein inflow, except in 13 patients with IVC thrombosis extending to the proximal portion of the renal vein inflow (n=7), with IVC stenosis below the renal vein inflow (n=5), or with duplicated IVC (n=1). For these patients, the filter was implanted in the IVC above the renal vein inflow. There was no misplacement, such as implantation in an iliac vein or other branch of the IVC, and no occurrence of major hemorrhage (decrease in hemoglobin level ≥2 g/dl or requirement for a blood transfusion), asymmetric dilation, tilting (≥20°) on post-implantation frontal and lateral views of the cavogram, displacement, damage to the IVC wall, fracture of the filter, infection, or air embolus associated with the procedure.
The purpose of the implantation is listed in Table 2 . Filters were not retrieved in 58 patients for the reasons listed in Table 3 . The filter was initially implanted permanently in patients because of age over 80 years (n=3), poor prognosis of other preexisting disease (n=21), and/or contraindication to anticoagulation therapy (n=13). In 21 patients GTFs were not retrieved, although retrieval had been planned initially, because of residual thrombus with the possibility of disengagement, such as the free-floating type, after treatment (n=15) and failure to retrieve (n=6). Attempts at retrieval were made in 66 patients, with 60 successful attempts. Consequently, the success rate of retrieval was 90.9%. In these patients, post-retrieval venography detected no damage to the IVC wall and no leakage of contrast media outside the blood vessels. During the retrieval process, 2 filters were dropped in the IVC, but were successfully retrieved with a retrieval kit. The mean duration of filter implantation was 10.1±6.2 days (2-37 days), and the average actual time to remove the filter was 6.1±5.4 min (2-40 min). No clinically evident pulmonary thromboembolism occurred during implantation or retrieval of the filters.
The longest interval from implantation to retrieval was 37 days. In that case, after the thrombus was successfully lysed Table 2 . with catheter-directed pharmacomechanical thrombolysis, a fraction of the thrombus was released and trapped within the filter. Additional systemic thrombolysis eliminated the trapped thrombus and the filter was retrieved. The retrieval procedure was easy, although the filter's struts were adhered lightly to the IVC wall. After retrieval, cavography and enhanced CT revealed no extravascular leakage or intraperitoneal hemorrhage. Among the 60 filters retrieved, inferior vena cavograms revealed 5 large thrombi trapped within (Fig 1) and in all 5 cases, the filters were successfully retrieved after additional pharmacological and/or pharmacomechanical thrombolysis eliminated the thrombus. Of the 58 patients with a permanent filter, 41 underwent follow-up CT for screening of thrombi around the filter more than 3 months post implantation (3-39 months, average 11.7 months). The other 17 patients were not followed up because of: death unrelated to pulmonary thromboembolism (n=11, cancer: 9, bleeding: 2), renal dysfunction (n=2), distance from hospital (n=1), or inadvertent oversight (n=3). Among the 41 patients followed up, 38 had filters that remained patent, making a patency rate of 92.7%. Of the 3 patients with occluded filters, 2 of them had the occlusion confirmed by CT at 9 and 36 months after implantation and did not receive anticoagulation therapy because of preexisting intracerebral bleeding (n=1) and cessation of follow-up (n=1). The third patient had an ovarian mucinous adenocarcinoma. Of the 41 patients, 35 received anticoagulation therapy (average INR 1.84±0.42), under which the filter patency rate was 97.1% (34/35). Only 1 patient, a 51-year-old man, developed a pulmonary thromboembolism during the mean observational period of 12.5±12.1 (1-40) months after implantation for permanent use. He also had contraindications to anticoagulation therapy because of cerebral hemorrhage. Three weeks after implantation, symptomatic pulmonary thromboembolism occurred, even though during that period he did not have symptoms suggestive of DVT.
We used enhanced CT to also assess the extent and frequency of penetration by filter struts. Penetration greater than 3 mm occurred in 23 patients, and more than 6 mm in 3 patients. However, neither leakage from the IVC nor injury to adjacent organs was observed (Fig 2) .
Discussion
Conventionally, surgical intervention, such as IVC liga- tion or plication, is used to prevent pulmonary thromboembolism caused by DVT, 21, 22 although percutaneous implantable filters for the IVC have also proven effective. [2] [3] [4] [5] [6] [7] According to a review of the use of permanent IVC filters by Becker et al, 6 recurrent clinical pulmonary embolism is rare after filter placement. Complications are common, but rarely life threatening, and among the reviewed studies only 0.16% of deaths were from complications. However, although permanent filters are effective in preventing acute pulmonary thromboembolism, it has been demonstrated that they significantly increase the rate of recurrence of DVT in the follow-up period. 8, 23 Therefore, it has been suggested that non-permanent filters be implanted for the acute period only, during which the risk of the thrombus disengaging is high. In Japan today there are 2 types of non-permanent filters: temporary and retrievable. 24 The temporary filter is useful because of the certainty that it can be removed, but there can be problems such as thrombosis (16%) and dislocation (4.8%). 9 The Japanese Society of Pulmonary Embolism Registry has reported that among 194 patients in Japan who received temporary filters, 10 patients developed filter-related infections (5.2%) and 3 filters were displaced (1.6%). 11 The retrievable filters used in the present study can be used permanently or temporarily. They can be implanted during the acute period of DVT when the thrombus is likely to disengage, and retrieved when no longer necessary after reduction or lysis of the thrombus. [25] [26] [27] In the present study the rate of recurrence of pulmonary thromboembolism did not differ between the GTF and other permanent filters, and there were no major complications around the site of insertion.
The GTF has advantages over the temporary type because it can be left in permanently if retrieval is difficult (ie, when a thromboembolus is trapped within the filter or pharmacological and/or pharmacomechanical thrombolysis fails to eliminate the thrombus and there is a risk of disengagement, such as with the free-floating type). 28 Furthermore, there were no cases of infection or filter displacement, and it has been reported that these risks are lower with retrievable IVC filters than with temporary filters, 11,29-31 probably because retrievable filters are not exposed outside the patient's body.
With regard to thrombi trapped in retrievable filters, Millward argues that although they may cause thromboembolism, a thrombus of 1×2 cm or less has minimal impact in patients with preserved cardiopulmonary function, and can be retrieved together with the filter. 20 In the present study, 5 patients had thromboemboli larger than that trapped in the filter, but additional pharmacological thrombolysis caused lysis and retrieval of the filter was successful.
The GTF proved to have considerable advantages over the conventional filters and is considered most appropriate for DVT with transient risk. However, although the GTF is useful for the treatment of DVT, it can be difficult to retrieve. In a previous study, 1 of 11 filters implanted in dogs was irretrievable by 2 weeks after implantation because they were firmly adhered to the vessel wall. 32 The venographic profile of the irretrievable filters in the present study also indicated that the hook of the filter was attached to the vein wall. Among 6 cases of retrieval failure, 2 patients were imaged by intravascular ultrasound to reveal the reason for the unsuccessful retrieval and in each case the filter's hook was found to be attached to the IVC wall and high-intensity echograms revealed fibrin deposits around the hook (Fig 3) . We therefore considered that turbulent flow had probably occurred around the hook attached to the IVC wall, inducing the deposition of fibrin, and both the adhesion of the hook to the IVC wall and the fibrin deposits interfered with efforts to snare the hook with the retrieval kit. Therefore, if an IVC filter is to be retrieved, care should be taken to avoid contact between the hook and the vascular wall and where possible, to keep the hook afloat with its open side facing the lumen. When using the right internal jugular vein approach, it is preferable to check the angle of the hook from 2 directions before its release, and repeat the implantation process if necessary.
A conclusion has not been reached as to the duration of implantation before retrieval, but the experiment in dogs indicates that firm adhesion starts between the filter and the vascular wall after 2-3 weeks. However, some researchers argue that adhesion occurs at a slower rate with anticoagulant therapy, 33 suggesting that intensive treatment with an anticoagulant may allow for an implantation period of up to 1 month. The longest period from implantation to retrieval reported to date is 317 days. 34 In the present study, there was no recurrence of symptomatic DVT in the patients with permanent implantation of a GTF. The PREPIC study found that symptomatic DVT occurred in 36% of patients with a permanent filter at 8-year follow-up, 33 but in that study, only 35% of patients were on anticoagulation therapy. In our study, 85% of patients with a permanent GTF received anticoagulation therapy, which is 1 of the reasons why there was no recurrence of symptomatic DVT.
We also evaluated the risk of IVC thrombus around the GTF in the chronic phase, because there are no previous reports of this. In this study, 33% of patients without anticoagulation therapy had total occlusion, whereas the patency rate of the filters was much higher in the patients on anticoagulant therapy (97%), which suggests that anticoagulation therapy after permanent implantation should be continued for the prevention of DVT recurrence and occlusion of the filter in the chronic phase.
We found that the filter struts had penetrated the IVC wall more than 3 mm in 23 patients; moreover, 3 filters had penetrated more than 6 mm. There was no leakage around the IVC, even in those patients under anticoagulation therapy (Fig 2) . The strut penetration did not induce complications such as retroperitoneal hemorrhage, surrounding organ damage, etc. However, penetration always carries a risk of complications, so improvement of the design of the struts is needed.
Although the GTF is useful for the management of DVT, its indications are still unclear. At present, the GTF is classified as retrievable, but evidence for the use of this type of filter is limited and the Japanese guideline 16 does not mention its usage. Therefore, use of this filter should be based on that of the temporary type and, in this instance, on the indications for a filter classified as class IIb according to the Japanese guideline. 16 However, retrieval-type filters may overcome the weakness of temporary filters and the indications may be extended with the accumulation of more data.
Conclusions
(1) The retrievable IVC filter used in this study was as effective as the conventional type for prevention of pulmonary thromboembolism caused by DVT in the lower extremities, pelvis, or IVC. (2) Complications seldom occurred, and the risks of infection and filter displacement were lower than with the use of the temporary filters. (3) Retrieval is simple, but care should be taken to avoid contact between the hook of the filter tip and the IVC wall when implanting. (4) Preference for the retrievable filter is expected to spread because of the fact that it can be implanted permanently but also retrieved when no longer necessary (eg, when the thrombus is lysed). (5) When used permanently, GTFs have a high patency rate and are effective in preventing pulmonary thromboembolism under low-intensity anticoagulation therapy.
A large follow-up study is necessary to examine the performance of the retrievable filter for permanent use, focusing on its preventive effect against pulmonary thromboembolism, prognosis, and occurrence of complications at a later date.
